[
  {
    "ts": null,
    "headline": "Alumis Stock Catapults More Than 100% As Biotech Takes On J&J, Protagonist In Psoriasis",
    "summary": "Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against J&J in psoriasis.",
    "url": "https://finnhub.io/api/news?id=57b94d4e4ba219781aced1c4470a69ad28d50a58cc4476c014010163a6e1296e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767707142,
      "headline": "Alumis Stock Catapults More Than 100% As Biotech Takes On J&J, Protagonist In Psoriasis",
      "id": 138000133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against J&J in psoriasis.",
      "url": "https://finnhub.io/api/news?id=57b94d4e4ba219781aced1c4470a69ad28d50a58cc4476c014010163a6e1296e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicatin",
    "url": "https://finnhub.io/api/news?id=35618bbddca324c9ab7a1c1a5b5a3801322a3d239aef02f01d90f21a37a863a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704580,
      "headline": "Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study",
      "id": 138000134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicatin",
      "url": "https://finnhub.io/api/news?id=35618bbddca324c9ab7a1c1a5b5a3801322a3d239aef02f01d90f21a37a863a6"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma",
    "summary": "Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by data from the Phase 3 MajesTEC-3 study demonstrating a statistically significant improvement in progression-free and overall survival compared to standard treatment1 Beerse, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced the submission of a Type II variation applicatio",
    "url": "https://finnhub.io/api/news?id=d50b2d3009922c6a913952a46b3df90d87be06404ca8024f46460280101c7974",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767700320,
      "headline": "Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma",
      "id": 137999366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by data from the Phase 3 MajesTEC-3 study demonstrating a statistically significant improvement in progression-free and overall survival compared to standard treatment1 Beerse, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced the submission of a Type II variation applicatio",
      "url": "https://finnhub.io/api/news?id=d50b2d3009922c6a913952a46b3df90d87be06404ca8024f46460280101c7974"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767695400,
      "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
      "id": 137999357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
      "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
    "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
    "url": "https://finnhub.io/api/news?id=242975ff118acdfa8cc397816bfab4fe69f8920d13f51886cda1ad7806ae12b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767692400,
      "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
      "id": 137999358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
      "url": "https://finnhub.io/api/news?id=242975ff118acdfa8cc397816bfab4fe69f8920d13f51886cda1ad7806ae12b1"
    }
  },
  {
    "ts": null,
    "headline": "CDT Capital Management 2025 Annual Partner Letter",
    "summary": "CDT Capital Management 2025 Annual Partner Letter",
    "url": "https://finnhub.io/api/news?id=58e98f61201265876e57a524a7e0def7bce78d4f07f67258b0b7f85ac942038f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767681000,
      "headline": "CDT Capital Management 2025 Annual Partner Letter",
      "id": 137999279,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=58e98f61201265876e57a524a7e0def7bce78d4f07f67258b0b7f85ac942038f"
    }
  },
  {
    "ts": null,
    "headline": "CDT Capital Management 2024 Annual Partner Letter",
    "summary": "For the fifth consecutive year, CDT is proud to report a more than fair return for our partners.",
    "url": "https://finnhub.io/api/news?id=387146139d92264e5d842f160b5596a8107244cfd8217fe530ed932d3dc5f3a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767681000,
      "headline": "CDT Capital Management 2024 Annual Partner Letter",
      "id": 137999082,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1427537698/image_1427537698.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "For the fifth consecutive year, CDT is proud to report a more than fair return for our partners.",
      "url": "https://finnhub.io/api/news?id=387146139d92264e5d842f160b5596a8107244cfd8217fe530ed932d3dc5f3a9"
    }
  }
]